Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE
WEDNESDAY, Nov. 30, 2022 (HealthDay News) — For patients with isolated distal deep venous thrombosis (DVT), six additional weeks of rivaroxaban after an initial six-week course of treatment reduces the risk for recurrent venous thromboembolism, accor…
Learn More